Woburn, Mass. — May 4, 2021: Ethos Discovery today announced a multidisciplinary strategic research collaboration for Ethos-PUSH (Precision Medicine Umbrella Study for Hemangiosarcoma), a five-year, two-segment post hoc umbrella study aimed at finding a curative outcome for canine hemangiosarcoma and delivering new knowledge for human angiosarcoma.
Hemangiosarcoma is arguably the worst cancer affecting dogs. It can develop in any part of the body and has a high propensity to spread to other organs. It’s is not effectively treated with most existing treatments. This canine cancer shares many features with the highly aggressive human cancer, angiosarcoma, which is also of blood vessel origin and characterized by rapid spread. Ethos-PUSH aims to enroll 400 dogs and will include molecular studies of the cancer to accelerate drug development for dogs afflicted with this disease.
This unique collaboration allows each collaborator an opportunity to test their concept, in parallel with the clinical trial, to individually and collectively contribute to finding curative outcomes for hemangiosarcoma.
“This collaboration brings individuals from diverse organizations together in a new way to reach a common goal. Ethos Discovery is agnostic to the source of the solution and we believe that this type of collaboration provides a more efficient and thoughtful process to research,” said Chand Khanna, DVM, Ph.D., DACVIM (Oncology), President, Ethos Discovery and Chief Scientific Officer, Ethos Veterinary Health.
“I am excited about being part of this group and foresee opportunities for collaboration with each of the members,” added Will Hendricks Ph.D., Founder and Chief Science Officer, Vidium Animal Health, and Assistant Professor of Integrated Cancer Genomics, TGen.
The study design incorporates welcoming collaboration to include the best new ideas to the problem, an understanding that no single drug or approach will be the answer, and step-wise improvements taken from all parts of this prospective study that will deliver the desired curative outcomes. “This collaboration can produce the best results for our patients and is likely to profoundly improve the outcome for this devastating disease,” said Antonella Borgatti, DVM, MS, DACVIM (Oncology), DECVIM-CA, Associate Professor, University of Minnesota’s College of Veterinary Medicine.
A recent milestone of the study is accruing 50 of the 400 dogs needed.
List of Collaborators
- Chand Khanna, DVM, Ph.D., DACVIM (Oncology), President, Ethos Discovery and Chief Scientific Officer, Ethos Veterinary Health
- Antonella Borgatti, DVM, MS, DACVIM (Oncology), DECVIM-CA, Associate Professor, University of Minnesota’s College of Veterinary Medicine
- Jacob Cawley, MS, DVM, DACVIM (Oncology), Ethos Discovery Comparative Genomics Fellow, Postdoctoral fellow in Peter Scacheri’s lab at Case Western Reserve University
- Scott Coonrod, PhD., Judy Wilpon Professor of Cancer Biology and Director, Baker Institute for Animal Health, Cornell University’s College of Veterinary Medicine
- Will Hendricks Ph.D., Founder and Chief Science Officer, Vidium Animal Health and Assistant Professor Integrated Cancer Genomics Division, TGEN
- Won Yeong Kang, DVM, Ph.D, Associate Research Scientist, The Jackson Laboratory
- Jonathan Paul M. Mochel, DVM, MSc, Ph.D., DECVPT, Associate Professor, Iowa State University’s College of Veterinary Medicine
- Jaime Modiano, VMD, Ph.D., Perlman Professor of Oncology and Comparative Medicine, University of Minnesota’s College of Veterinary Medicine
- Corrie Painter, Ph.D., Associate Director of Operations and Scientific Outreach for the Broad Cancer Program, Broad Institute
- Sam Stewart, DVM, DACVECC, Science-Commercialization Fellow, Ethos Discovery
About Ethos Discovery
Ethos Discovery is a 501(c)3 nonprofit organization devoted to developing innovative medical treatments and tests that benefit both pets and humans. Through targeted research, clinical trials, and the delivery of advanced veterinary care, we seek to address unmet clinical needs to improve health outcomes for humans and animals with complex medical problems.
Ethos Discovery is uniquely positioned, with the support of Ethos Veterinary Health, to reach patients and doctors nationally and to partner with key international leaders in their field. This flexibility provides us the opportunity to pursue impactful research that will make a difference where it is most important, within clinical hospitals and for patients and families. Scientific Programs are currently focused on: Sarcoma, Sepsis, Inflammatory Brain Disease, Dysbiosis, Therapeutics, and Surgical Innovations.